ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation
DNA methylation · human · 12 samples
- What it is
- DNA methylationChemical marks on DNA that help switch genes on or off.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × BPH1 dCas9 vs 3 × BPH1 Empty_Vector vs 3 × BPH1 ZC3H13 OE vs 3 × BPH1 ZC3H13 KOGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA MethylationCancer research · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE309246_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for beta-value tables or raw IDAT files among the supplementary files.
Also filed as BioProject PRJNA1334414 and SRA study SRP627371. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9263589 BPH1 dCas9 replicate 1 BPH1 dCas9
- GSM9263590 BPH1 dCas9 replicate 2 BPH1 dCas9
- GSM9263591 BPH1 dCas9 replicate 3 BPH1 dCas9
- GSM9263592 BPH1 Empty_Vector replicate 1 BPH1 Empty_Vector
- GSM9263593 BPH1 Empty_Vector replicate 2 BPH1 Empty_Vector
- GSM9263594 BPH1 Empty_Vector replicate 3 BPH1 Empty_Vector
- GSM9263595 BPH1 ZC3H13 OE replicate 1 BPH1 ZC3H13 OE
- GSM9263596 BPH1 ZC3H13 OE replicate 2 BPH1 ZC3H13 OE
- GSM9263597 BPH1 ZC3H13 OE replicate 3 BPH1 ZC3H13 OE
- GSM9263598 BPH1 ZC3H13 KO replicate 1 BPH1 ZC3H13 KO
- GSM9263599 BPH1 ZC3H13 KO replicate 2 BPH1 ZC3H13 KO
- GSM9263600 BPH1 ZC3H13 KO replicate 3 BPH1 ZC3H13 KO
- GSE239676 Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response 68 samples shares progression, metastatic
- GSE261171 High-Resolution Single-Cell RNA Sequencing Uncovers Disparate Neutrophil Populations within Metastatic Cancer Lesions Linked to Progression Free Survival in Multiple Myeloma Patients 28 samples shares progression, metastatic
- GSE302864 DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer 12 samples shares progression, drives
- GSE292130 Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation [scRNA-seq] 31 samples shares progression, methylation
- GSE304097 DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression 293 samples shares progression, methylation
- GSE279619 SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation. 124 samples shares methylation, loss
- GSE324815 Intratumoral CD40 agonist sotigalimab in combination with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: Results of a phase 1/2 study 24 samples shares metastatic, drives
- GSE289582 Baseline tumor features and peripheral blood immune dynamics that underlie efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab [Blood] 115 samples shares metastatic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.